CRISPR Therapeutics (CRSP) Q2 2026 earnings summary

Executive summary

• Focused on developing CRISPR-based therapeutics across hemoglobinopathies, in vivo approaches, CAR-T, and regenerative medicine, with CASGEVY as the first approved CRISPR-based therapy for SCD and TDT, now expanded to pediatric use in the US.

• Achieved strong portfolio execution in Q2 2026, highlighted by significant regulatory and clinical milestones, including FDA approval for CASGEVY in children as young as 2.

• Pipeline includes in vivo liver editing, siRNA-based programs (notably CTX611 in Phase 2), next-generation CAR-T therapies, and regenerative medicine candidates for diabetes, with several Phase 1 trials initiated or ongoing.

• Strategic partnerships with Vertex and Sirius drive co-development and commercialization, with additional collaborations in DMD, DM1, and diabetes.

• Expanded autoimmune and immuno-oncology pipeline, including new trials for zugo-cel and proprietary CAR-T platforms.

Financial highlights

• Q2 2026 revenue was $10.2M, up from $0.9M in Q2 2025, mainly from an upfront payment on a new license and collaboration agreement and CASGEVY sales.

• Net loss for Q2 2026 was $91.2M, a significant improvement from $208.5M in Q2 2025, driven by lower R&D and collaboration expenses and absence of large one-time charges.

• Operating expenses for Q2 2026 were $127.5M, down from $230.2M in Q2 2025.

• Cash, cash equivalents, and marketable securities totaled $2.36B as of June 30, 2026.

• Issued $600M in convertible senior notes in March 2026, with net proceeds of $585.4M.

Outlook and guidance

• Existing cash and investments expected to fund operations for at least 24 months.

• Anticipates continued losses as R&D and G&A expenses persist, with additional capital needs likely for long-term development and commercialization.

• Anticipates multiple clinical updates in H2 2026, including for CTX310, CTX611, and zugo-cel programs.

• Regulatory submissions for CASGEVY in additional geographies and age groups are underway.

• Expects continued expansion of in vivo and siRNA-based pipelines, with further updates in 2026.